Evidence map›Paper›PMID 38817600›Full record

ReviewFrontiers in immunology2024

Immune checkpoints: new insights into the pathogenesis of thyroid eye disease.

Xingyi Shu, Yuchao Shao, Yuqing Chen, Chengcheng Zeng, Xiao Huang, Ruili Wei

Abstract readReview
PubMed Full text at PMC Publisher
In one paragraph

Review in Frontiers in immunology, 2024. The graph could read no effect estimate from its abstract, so it casts no vote on the map. Cited by 15 papers, 1 of them a synthesis that pooled it.

0numbers the graph read from it
0cells of the map it votes in
15citing papers in PubMed, 1 pooled it
–field-weighted citation impact
1 · What the graph read from it

What it found

Each row is one number read from the abstract, on the scale the paper reported it, with its interval. Left of the dashed line favours the treatment, right favours the comparator. Under each row is the sentence it came from. New to these charts? A ten-minute tutorial.

The abstract states no effect estimate the extractor could read, or names no intervention and outcome on the map, so this paper lights no cell and moves no belief. It is still indexed, cited and linked below.

2 · The registry

The trial behind it

Trials whose registry record cites this paper, or whose number appears in the abstract. A trial that started after this paper was published is citing it as background, not reporting it.

Neither the registry nor the abstract names a trial number. If this is a trial report, that itself is worth knowing.

3 · Its place in the literature

Who cites it

15 citing papers in PubMed, 1 synthesis or guideline pooled it.

  1. Pooled it
  2. Article
  3. Review
  4. Article
  5. Observational
  6. Review
  7. Review
  8. Review
  9. Article
  10. Article
  11. Review
  12. Article
  13. Review
  14. Article
  15. Article
4 · The record

Corrections and comments

PubMed lists nothing against this paper. Absence here is not a guarantee, only a check that was made.

5 · Who and what money

Authors and funding

6 authors.

Xingyi Shu *Department of Ophthalmology, Changzheng Hospital of Naval Medicine University, Shanghai, China.
Yuchao Shao *Department of Ophthalmology, Changzheng Hospital of Naval Medicine University, Shanghai, China.
Yuqing ChenDepartment of Ophthalmology, Changzheng Hospital of Naval Medicine University, Shanghai, China.
Chengcheng ZengDepartment of Ophthalmology, Changzheng Hospital of Naval Medicine University, Shanghai, China.
Xiao HuangDepartment of Ophthalmology, Changzheng Hospital of Naval Medicine University, Shanghai, China.
Ruili WeiDepartment of Ophthalmology, Changzheng Hospital of Naval Medicine University, Shanghai, China.

Funding

No grant is acknowledged in the PubMed record.

6 · The paper itself

Abstract

Thyroid eye disease (TED) is a disfiguring autoimmune disease characterized by changes in the orbital tissues and is caused by abnormal thyroid function or thyroid-related antibodies. It is the ocular manifestation of Graves' disease. The expression of thyroid-stimulating hormone receptor (TSHR) and the insulin-like growth factor-1 receptor (IGF-1 R) on the cell membrane of orbital fibroblasts (OFs) is responsible for TED pathology. Excessive inflammation is caused when these receptors in the orbit are stimulated by autoantibodies. CD34

Indexed as

Graves OphthalmopathyImmune Checkpoint InhibitorsAnimalsAutoantibodiesHumansImmune Checkpoint ProteinsReceptor, IGF Type 1Receptors, ThyrotropinAutoantibodiesImmune Checkpoint InhibitorsImmune Checkpoint ProteinsReceptor, IGF Type 1Receptors, Thyrotropinimmune cellsimmune checkpointsteprotumumabtherapeutic targetsthyroid eye disease

Identifiers

PMID38817600
PMCPMC11137266

What Socratic holds

Textmetadata
LicenceCC BY
Read underepoch 390

Registered trials

None linked

Read under generation 80e0d062 · epoch 390. Bibliography from PubMed, PubMed Central and OpenAlex; grants from NIH RePORTER; trial links from ClinicalTrials.gov; estimates, votes and beliefs from the Socratic graph.